Targeting a Rare Blood Cancer: Blastic Plasmacytoid Dendritic Cell Neoplasm
The molecularly targeted therapeutic tagraxofusp-erzs is the first ever treatment approved by the FDA for the treatment of blastic...
Progress Against Cancer
The molecularly targeted therapeutic tagraxofusp-erzs is the first ever treatment approved by the FDA for the treatment of blastic...
The FDA approval of calaspargase pegol-mknl provides a longer-acting chemotherapy option for certain patients with acute lymphoblastic leukemia. The...
The FDA approval of pembrolizumab for treating certain patients with Merkel cell carcinoma makes it the second immunotherapeutic approved...
The FDA approval of gilteritinib provides a new treatment option for certain patients whose acute myeloid leukemia tests positive...
The FDA approval makes larotrectinib the first molecularly targeted therapeutic approved for use based on a tumor biomarker rather...
The FDA recently approved two molecularly targeted therapeutics for treating patients newly diagnosed with acute myeloid leukemia (AML) who...
The FDA approval of pembrolizumab for treating certain patients with liver cancer makes it the second immunotherapeutic approved for...
The U.S. Food and Drug Administration adds a fifth molecularly targeted therapeutic option for the treatment of ALK-positive lung...
The FDA approval of talazoparib means there are now two PARP inhibitors that can be used to treat patients...
The FDA adds a fifth molecularly targeted therapeutic option for the treatment of lung cancer driven by EGFR mutations....